Toripalimab combined with anlotinib was tolerable in EGFR-TKI-resistant advanced NSCLC patients not previously treated with chemotherapy. Patients without detectable EGFR mutation and high soluble PD-L1 levels may benefit from this chemotherapy-free treatment.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- phase ii study
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- stem cells
- squamous cell carcinoma
- clinical trial
- randomized controlled trial
- open label
- mesenchymal stem cells
- patient reported outcomes
- combination therapy
- rectal cancer
- smoking cessation
- double blind
- brain metastases